Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions End Stage Liver Disease, Jaundice, Liver...
Phase Not Applicable
Enrollment 411
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

In this study, a single non-invasive tool, spleen stiffness measurement (SSM), was used to monitor the disease regression of inpatients with chronic liver disease (CLD) and acute liver injury. The present study aimed to establish an early diagnosis warning model for acute-on-chronic liver failure (ACLF) by SSM and investigate the effect of dynamic changes in SSM on the short-term prognosis (28-day, 90-day morbidity and mortality) of inpatients with CLD and acute liver injury.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: FibroScan® Expert 630 — The SSM by FibroScan 630 was first performed after admission, repeated at the day 5±2 as soon as feasible, and finally evaluated before discharge.

Primary Outcomes

  • 90-day transplant-free mortality (Day 90)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-01-01
Completion: 2025-12-30
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 411 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nanfang Hospital, Southern Medical University
Principal Investigators:
  • Jinjun Chen, PHD (PRINCIPAL_INVESTIGATOR) - Nanfang Hospital, Southern Medical University
Contact Information
Study Contact:
Jinjun Chen, PHD
86-18588531001
chjj@smu.edu.cn
Jinjun Chen, PHD
86-18588531001
chjj@smu.edu.cn
Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University
Interventions
  • Device: FibroScan® Expert 630 — The SSM by FibroScan 630 was first performed after admission, repeated at the day 5±2 as soon as feasible, and finally evaluated before discharge.
Study Locations (1 sites)
Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515 China
Eligibility Criteria
Inclusion Criteria: 1. Age between 18 years and 80 years 2. Chronic liver diseases regardless of etiology 3. Acute liver injury with total bilirubin ≥ 3 mg/dl regardless of inducement Exclusion Criteria: 1. Prior surgery of liver diseases before enrollment such as liver transplantation, transjugular intrahepatic portosystemic shunt (TIPS), splenectomy and partial splenic embolization 2. Severe extrahepatic diseases such as chronic obstructive pulmonary disease level IV, chronic kidney disease with end-stage renal failure, myocardial infarction within 3 months before admission 3. Receiving Immunosuppressive drugs for reasons rather than chronic liver diseases 4. Diagnosis of hepatocellular carcinoma or other non-liver malignancies during screening period 5. Serious mental illnesses such as anxiety, depressive disorders to obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) 6. The pregnant 7. Jaundice due to biliary obstruction or cholestasis 8. Unsuitable to participate in this study judging by investigators

Nailfold Capillaroscopy in PH

NCT07768644
Recruiting
Conditions Pulmonary Arterial Hypertension (PAH) (W...
Phase Not Applicable
Enrollment 60
Locations 1 sites
Compensation Compensation or reimbursement is mentioned in the public study record; confirm details with the study team.
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

Pulmonary hypertension (PH) is an uncommon condition and can often be difficult to diagnose. It means elevated blood pressure in the lungs which can rapidly lead to failure of the right side of the heart and is ultimately fatal. Diagnosing PH currently involves a number of scans, breathing tests and often an invasive test called right heart catheterisation \[RHC\] (which involves inserting a tube into a large vein to measure the lung blood pressure from the). The investigators propose using a scan of the nailbeds called "Nailfold (Video) Capillaroscopy" to see whether this measurements correspond to the pressures that the investigators measure at the time of RHC and whether these measures change with treatment for PH. The investigators wish to answer the hypotheses that: 1. The measurements of the nailbed blood vessels are correlated with the invasive right heart catheter values across all groups of PH 2. The abnormalities seen in systemic sclerosis are reversible with treatment with pulmonary vasodilator drugs 3. This change will be significantly more than any change seen in other types of pulmonary hypertension with these drugs 4. Changes in the nailbed blood vessels with treatment will reflect changes in the usual parameters used to measure treatment response in PH: The scan uses a camera microscope connected to a laptop, does not involve radiation and can be completed within 30 minutes. The results are sent to the University of Manchester where they are analysed by computer software. If patients are found to have pulmonary hypertension and are started on medication (pulmonary vasodilators) to open up the blood vessels of the lungs, the investigators will then repeat the scan at this point. The investigators will compare the results between different forms of PH before and after treatment.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: Standard of Care therapy — Pulmonary Vasodilator therapy which may include: * Phosphodiesterase Inhibitors * Prostanoids * Endothelin Receptor Antagonists * Activin Ligand Traps

Primary Outcomes

  • Linear Capillary Density (4 - 6 months into therapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-05-20
Completion: 2028-08-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Glasgow
Principal Investigators:
  • Alistair C Church, PhD, BSc, MB ChB, FRCP (PRINCIPAL_INVESTIGATOR) - University of Glasgow / NHS Greater Glasgow and Clyde
Contact Information
Study Contact:
William J Kerrigan, BA BMBCh MRCP
0141 951 5497
w.kerrigan.1@research.gla.ac.uk
Alistair C Church, PhD, BSc, MB ChB, FRCP
0141 951 5497
alistair.church@glasgow.ac.uk
William J Kerrigan, BA BMBCh MRCP
01419515497
w.kerrigan.1@research.gla.ac.uk
NHS Golden Jubilee
Interventions
  • Drug: Standard of Care therapy — Pulmonary Vasodilator therapy which may include: * Phosphodiesterase Inhibitors * Prostanoids * Endothelin Receptor Antagonists * Activin Ligand Traps
Study Locations (1 sites)
NHS Golden Jubilee, Clydebank, West Dunbartonshire G81 4DY United Kingdom
Eligibility Criteria
Inclusion Criteria: For inpatient enrolment: * Suspected diagnosis of group 1,3 or 4 pulmonary hypertension undergoing inpatient assessment at nationally designated centre * Age \> 18 years For follow up scanning of those enrolled as an inpatient: * Confirmed diagnosis of pulmonary hypertension assessed at nationally designated centre fulfilling criteria for group 1, 3 or 4 disease * Commencing PH targeted therapy, specifically one or more of: a phosphodiesterase 5 inhibitor (PDE5i), an ET receptor antagonist (ERA), parenteral prostanoid therapy, selexipag, riociguat, sotatercept. For outpatient enrolment * Confirmed diagnosis of pulmonary hypertension assessed at nationally designated centre fulfilling criteria for group 1, 3 or 4 disease * Age \> 18 years * Escalating PH targeted therapy, specifically one or more of: a phosphodiesterase 5 inhibitor (PDE5i), an ET receptor antagonist (ERA), parenteral prostanoid therapy, selexipag, riociguat, sotatercept. Target of \> 25% of patients recruited at diagnosis and to have an SSc-spectrum disorder fulfilling either ACR/EULAR 2013 or VEDOSS (very early diagnosis of SSc) criteria. Target of \> 25% of patients recruited at diagnosis and to have non-SSc group 1 (PAH) diagnosis (as determined by national MDT decision). Exclusion Criteria: * Patients with confirmed group 2 or group 5 pulmonary hypertension * Patients \< 18 years of age * Patients unable to participate in nailbed microscopy (through e.g. amputation, severe contractures or other musculoskeletal issues). * (From follow up) Patients not being commenced on pulmonary vasodilator therapy at the point of diagnosis. * Patients already on maximal PH therapy * Patients lacking capacity to consent to participation * Patients who are non-fluent English speakers, where suitable translation cannot be found within a time frame that makes the study feasible. * Patients with a life expectancy \< 4 months * Patients who have consumed nicotine or caffeine within the last 4 - 6 hours * Patients wearing nail polish / varnish/ extensions that preclude adequate nailbed visualisation.
Conditions Overweight, Obesity, Hypertensive
Phase PHASE3
Enrollment 336
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

A multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of IBI362 in participants with mild to moderate hypertension complicated by overweight/obesity who have not received antihypertensive drug treatment

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: IBI362 — IBI362 will be administered subcutaneously once weekly (QW) in a step-up dose titration regimen over 48 weeks: * Weeks 1-4: 2 mg QW * Weeks 5-8: 4 mg QW * Weeks 9-24: 6 mg QW * Weeks 25-48: 6/9 mg QW.
  • Drug: Placebo — Matching placebo will be administered subcutaneously once weekly (QW) for 48 weeks, with the same number of injections as the IBI362 group to maintain study blinding.

Primary Outcomes

  • To evaluate the effect of IBI362 on mean sitting systolic blood pressure (msSBP) compared with placebo at Week 16 of treatment. (Week 16)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-04-23
Completion: 2027-04-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 336 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Contact Information
Study Contact:
Jie Wei
0512-69566088
jie.wei@innoventbio.com
Weiwei Jiang
021-64150275
gcp@rjh.com.cn
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Interventions
  • Drug: IBI362 — IBI362 will be administered subcutaneously once weekly (QW) in a step-up dose titration regimen over 48 weeks: * Weeks 1-4: 2 mg QW * Weeks 5-8: 4 mg QW * Weeks 9-24: 6 mg QW * Weeks 25-48: 6/9 mg QW.
  • Drug: Placebo — Matching placebo will be administered subcutaneously once weekly (QW) for 48 weeks, with the same number of injections as the IBI362 group to maintain study blinding.
Study Locations (1 sites)
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai Municipality China
Eligibility Criteria
Inclusion Criteria: 1. Aged ≥ 18 years old at the time of signing the informed consent form. 2. Confirmed diagnosis of hypertension. 3. No prior history of antihypertensive medication treatment at screening; or previously received only one type of antihypertensive medication during the same period and has discontinued all antihypertensive medications for at least 2 weeks prior to screening. 4. Voluntarily sign the informed consent form and be willing to strictly comply with the requirements and restrictions stated in the informed consent form and the protocol throughout the study, including but not limited to: maintaining a stable diet and exercise routine, receiving the study drug injections as scheduled, and keeping a study diary. Exclusion Criteria: 1. The investigator suspects that the participant may be allergic to the components of the study drug or drugs of the same class. 2. History of orthostatic hypotension, or blood pressure measured at screening meeting the criteria for orthostatic hypotension. 3. History or diagnostic evidence of secondary hypertension other than obstructive sleep apnea, including but not limited to: renal parenchymal hypertension, renovascular hypertension (unilateral or bilateral renal artery stenosis), aortic stenosis, primary aldosteronism, Cushing's syndrome, pheochromocytoma, polycystic kidney disease, and drug-induced hypertension. 4. Concurrent use of beta-blockers within 1 month prior to screening. 5. Self-reported body weight change \> 5 kg within 3 months. 6. History of acute myocardial infarction, unstable angina pectoris, coronary artery bypass grafting, percutaneous coronary intervention (excluding diagnostic angiography), large artery aneurysm or dissecting aneurysm, transient ischemic attack (TIA), cerebrovascular accident, severe arrhythmia (e.g., ventricular fibrillation, ventricular flutter, atrial fibrillation, atrial flutter, second-degree or higher atrioventricular block, sick sinus syndrome, etc.) within 6 months; or history of decompensated heart failure or heart failure of New York Heart Association (NYHA) Class III or IV; or history of severe diseases such as epilepsy or syncope, which the investigator deems unsuitable for trial participation. 7. Confirmed diagnosis of diabetes mellitus, or laboratory tests showing glycated hemoglobin (HbA1c) ≥ 6.5%, fasting blood glucose ≥ 7 mmol/L and/or random blood glucose ≥ 11.1 mmol/L. 8. History of acute or chronic pancreatitis, pancreatic injury, acute cholecystitis, acute cholangitis, or symptomatic/treated gallbladder disease (except for participants who have undergone cholecystectomy and are judged eligible by the investigator); or serum amylase or lipase \> 2.0 × Upper Limit of Normal (ULN); or fasting serum triglycerides ≥ 5.64 mmol/L (500 mg/dl). 9. Chronic gastrointestinal diseases or systemic diseases that may affect gastrointestinal motility at screening, or use of drugs that may alter gastrointestinal motility, appetite or absorption within 3 months prior to screening. 10. History or relevant family history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) type 2A or 2B.
Conditions Diabetes Mellitus, Hypertension
Phase NA
Enrollment 1022
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

CHRONICLE is a randomized trial assessing the comparative effectiveness of providing written visit information via the patient portal (NOTES) versus NOTES plus visit audio recording (AUDIO) to older adult patients with chronic diseases on quality of life and other outcomes. During the trial, the team will also invite caregivers identified by patients to join the project.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: NOTES — The intervention will include: (1) a brief training on using the patient portal to access written visit information with assistance in setting up patient portal accounts where necessary (including strategies to share notes with a caregiver), (2) post-visit reminders to use the patient portal to access written visit information.
  • Other: AUDIO — The intervention will include: (1) audio recording all visits with the study clinician for six months, (2) training on how to record visits and access visit recordings, and (3) post-visit reminders listen to the visit recordings.

Primary Outcomes

  • Quality of Life - Mental functioning (6 months from enrollment)
  • Quality of Life - Physical functioning (6 months from enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-01-24
Completion: 2027-06-14
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1022 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Dartmouth-Hitchcock Medical Center
Collaborators: The University of Texas Medical Branch, Galveston, Vanderbilt University Medical Center, Beth Israel Deaconess Medical Center, Patient-Centered Outcomes Research Institute
Principal Investigators:
  • Paul J Barr, PhD (PRINCIPAL_INVESTIGATOR) - Dartmouth College
  • Kerri L Cavanaugh, MD (PRINCIPAL_INVESTIGATOR) - Vanderbilit University Medical Center
  • Meredith C Masel, PhD (PRINCIPAL_INVESTIGATOR) - University Texas Medical Branch
Contact Information
Study Contact:
Paul J Barr, PhD
603-646-7016
paul.j.barr@dartmouth.edu
Renata W. Yen, PhD
603-646-5670
renata.west.yen@dartmouth.edu
Paul J Bar, PhD
603-646-7016
paul.j.barr@dartmouth.edu
Dartmouth Hitchcock Clinics Manchester
Interventions
  • Other: NOTES — The intervention will include: (1) a brief training on using the patient portal to access written visit information with assistance in setting up patient portal accounts where necessary (including strategies to share notes with a caregiver), (2) post-visit reminders to use the patient portal to access written visit information.
  • Other: AUDIO — The intervention will include: (1) audio recording all visits with the study clinician for six months, (2) training on how to record visits and access visit recordings, and (3) post-visit reminders listen to the visit recordings.
Study Locations (3 sites)
Dartmouth Hitchcock Clinics Manchester, Manchester, New Hampshire 03104 United States
Vanderbit University Medical Center, Nashville, Tennessee 37232 United States
University of Texas Medical Branch, Galveston, Texas 77555 United States
Eligibility Criteria
PATIENTS: Inclusion Criteria: * ≥ 65 years; * With multimorbidity (diabetes or hypertension plus one of the following: arthritis (osteoarthritis and rheumatoid arthritis), asthma, atrial fibrillation, Alzheimer's disease and related dementia (not severe), cancer, chronic obstructive pulmonary disease, depression, heart disease, heart failure, hyperlipidemia, osteoporosis, kidney disease and stroke. Patients with diabetes plus hypertension are eligible. * Have had two or more clinic visits in the previous 12 months; * Plan on receiving ongoing care at the clinic with the enrolled clinician for the subsequent 6 months; * Do not have vision or hearing problems that cannot be corrected; and * Have not recorded a clinic visit for personal use in the past 6 months Exclusion Criteria: * With no capacity to consent to the project; * With schizophrenia and other psychotic disorders, current substance-use disorders, uncorrected hearing or visual impairment with no adjustments to support accessing the interventions or surveys; * Living in skilled nursing homes or hospice, because they engage less in self-management; * With cognitive impairment as identified by a score of ≤4 on the six-item screener (SIS) * Lacking internet access; * Who do not speak English or Spanish; * Who (i) do not have access to a personal email, (ii) do not have an email address shared with a family member or patient-identified caregiver, and/or (iii) are not interested in creating a personal email as this would prevent them from engaging with the intervention(s); and * Who do not wish to create a patient portal account, if they do not already have one as this would prevent them from engaging with the intervention(s). CAREGIVERS: Inclusion criteria: * Agree to their identified role as a caregiver; * Speak English or Spanish; * Have capacity to consent to research participation; and * ≥ 18 years. Exclusion criteria: * No capacity to consent to the project; * Living in skilled nursing homes or hospice; * Lacking internet access; or * Do not speak English or Spanish
Conditions Hypertension
Phase PHASE1, PHASE2
Enrollment 70
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

There is strong evidence suggesting that endoplasmic reticulum stress contributes to neurogenic and vascular hypertension in various animal models, however this has never been explored in humans. Therefore, this project will fill this gap by performing a single-blind, placebo-controlled trial in humans with hypertension.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Single

Interventions / Regimen

  • Drug: TUDCA — Endoplasmic reticulum stress will be inhibited by chronic (8 weeks) oral ingestion of the dietary supplement tauroursodeoxycholic acid (TUDCA; 1,750 mg/day)
  • Drug: Placebo — Placebo pills containing microcrystalline cellulose will be ingested over the course of the 8 week intervention.

Primary Outcomes

  • 24 hour Blood Pressure (Within 1-2 weeks before and after intervention or placebo)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2023-08-15
Completion: 2028-12-31
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of North Texas Health Science Center
Contact Information
Study Contact:
Steven A Romero, PhD
8177355159
steven.romero@unthsc.edu
University of North Texas Health Science Center
Bella Ruiz, BS
8177352088
YsabellaRuiz@my.unthsc.edu
University of North Texas Health Science Center
Interventions
  • Drug: TUDCA — Endoplasmic reticulum stress will be inhibited by chronic (8 weeks) oral ingestion of the dietary supplement tauroursodeoxycholic acid (TUDCA; 1,750 mg/day)
  • Drug: Placebo — Placebo pills containing microcrystalline cellulose will be ingested over the course of the 8 week intervention.
Study Locations (1 sites)
University of North Texas Health Science Center, Fort Worth, Texas 76107 United States
Eligibility Criteria
Inclusion Criteria: 1. 18 to 80 years of age 2. No tobacco/nicotine use within preceding 6 months (e.g., cigarettes, chewing tobacco, nicotine gum or patches) 3. Systolic blood pressure \<140 mmHg; diastolic blood pressure \<90 mmHg (obtained at the Screening and Familiarization Visit) 4. Normal 12-lead ECG (obtained at the Screening and Familiarization Visit and reviewed by a board-certified physician) 5. Normal clinical results from a medical exam reviewed by a board-certified physician (e.g., General Health Questionnaire obtained at the Screening and Familiarization Visit) 6. Body mass index (BMI) \<35 unless athletic/muscular build; calculation = body weight (kg)/height (m2); 7. Females only: documentation of a negative pregnancy test prior to the familiarization and experimental sessions unless post-menopausal Exclusion Criteria: 1. Not meeting the defined age criteria 2. Body mass index (BMI) \>35 unless athletic/muscular build; calculation = body weight (kg)/height (m2) 3. Any tobacco/nicotine use within the last 6 months (e.g., cigarettes, chewing tobacco, nicotine gum or patches) 4. Positive pregnancy test 5. Females with an erratic/irregular menstrual cycle 6. Females who are breastfeeding 7. Women who are prescribed a continually releasing hormonal contraceptive (e.g. NuvaRingTM or other hormone releasing vaginal rings, Depo Provera shot, or birth control implants such as Nexplanon) 8. Subjects who weigh less than 80 lbs. 9. Use of prescription drugs, non-prescription drugs, dietary supplements or herbal medicines known to alter vascular function unless cleared prior to the study 10. Use of beta blockers 11. Daily use of bronchodilators 12. Use of anti-coagulant therapy 13. Implanted medical devices (e.g. cardiac pacemaker) 14. Current or past history of hyperthyroidism, or other thyroid hormone-related disease 15. Current use of hormone replacement therapy (e.g., estrogen, testosterone) 16. HbA1c \>5.6 17. Resting systolic blood pressure of \<100 mmHg; \>140mmHg or diastolic blood pressure \>90mmHg 18. Abnormal 12-lead ECG or uncontrolled heart rhythm issues causing symptoms, or an unstable blood pressure 19. History of cerebrovascular abnormalities (e.g., prior stroke, transient ischemic attacks, epilepsy) 20. Known history of atherosclerosis of the carotid arteries (i.e., plaque formation) 21. History of concussion and or other loss of consciousness within the preceding 30 days 22. Autonomic dysfunction (e.g., Shy-Drager Syndrome, Bradbury-Eggleston syndrome, sinus arrhythmia, idiopathic orthostatic hypotension, fainting disorder) 23. Respiratory illnesses (e.g., chronic asthma (including exercise-induced asthma), Chronic Obstructive Pulmonary Disease, Reactive Airway Disease) 24. Any prior history of anaphylaxis, not just prior reactions to the materials used in this study 25. Severe phobia of needles 26. Latex allergy aa) Known allergies or sensitivities to substances used in the study (e.g., Lidocaine HCL, sodium nitroprusside, acetylcholine, phentolamine, L-NAME, TUDCA, or related drugs) bb) Donated blood within the last 60 days cc) History or family history of abnormal blood clotting, clots in deep veins in the legs or pelvis, or blood clots to the lungs dd) History of alcohol or drug abuse which inhibits the subject's ability to complete this study ee) Individuals who have had mastectomies ff) History of methemoglobinemia gg) Current diagnosis of anemia hh) Current Fever (oral temp \>99.5 °F/ 37.5 °C) ii) Current use of PDE3 inhibitors (e.g., Viagra) or soluble guanylate cyclase (sGC) stimulators (e.g., riociguat), or unwillingness to withhold medication for 2 weeks prior to laboratory testing jj) Current diagnosis of cancer kk) Cardiac surgery or cardiac events (e.g., coronary artery bypass graft surgery, myocardial infarction, heart failure) ll) Diagnosis of neurological disease or cognitive dysfunction

Glaucoma Related Quality of Life

NCT07510087
Recruiting
Conditions Glaucoma
Phase Not Applicable
Enrollment 5000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

Subjects with a diagnosis of glaucoma will be handed out different quality of life related questionnaires and their score will be evaluated at baseline and 3-6 months after treatment or surgery was initiated/performed.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: GQL-15 — GQL-15 questionnaire
  • Other: Glaucoma Symptom Scale — GSS questionnaire
  • Other: NEI Vision Function Questionnaire — Vision function questionnaire
  • Other: Ocular Surface Disease Index — OSDI questionnaire

Primary Outcomes

  • Ocular Surface Disease Index (OSDI) (At baseline and 3-6 months after glaucoma treatment (i.e. drops, SLT, or surgery) was initiated/performed.)
  • Glaucoma Symptom Scale (GSS) (At baseline and 3-6 months after glaucoma treatment (i.e. drops, SLT, or surgery) was initiated/performed.)
  • National Eye Institute Visual Function Questionaire (NEI VFQ) (At baseline and 3-6 months after glaucoma treatment (i.e. drops, SLT, or surgery) was initiated/performed.)
  • Glaucoma Quality of Life-15 (GQL-15) (At baseline and 3-6 months after glaucoma treatment (i.e. drops, SLT, or surgery) was initiated/performed.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-12-30
Completion: 2027-05-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 5000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Marc Toeteberg-Harms
Contact Information
Study Contact:
Marc Toeteberg-Harms, MD
+1 319 356 3938
marc-toeteberg-harms@uiowa.edu
Helen Gomez Study Coordinator
+1 319 356 3938
helen-gomez@uiowa.edu
Marc Toeteberg-Harms, MD
+1 319 356 3938
marc-toeteberg-harms@uiowa.edu
University of Iowa, Dept. of Ophthalmology & Visual Sciences
Interventions
  • Other: GQL-15 — GQL-15 questionnaire
  • Other: Glaucoma Symptom Scale — GSS questionnaire
  • Other: NEI Vision Function Questionnaire — Vision function questionnaire
  • Other: Ocular Surface Disease Index — OSDI questionnaire
Study Locations (1 sites)
University of Iowa, Dept. of Ophthalmology & Visual Sciences, Iowa City, Iowa 52242 United States
Eligibility Criteria
Inclusion: * diagnosis of glaucoma (open- as well as closed-angle glaucoma, primary and secondary glaucomas) * 18 years of age or older with no upper limit * male and female subjects Exclusion: * absence of a diagnosis of glaucoma * less than 18 years of age
Conditions Pulmonary Arterial Hypertension
Phase PHASE3
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to determine if there is a greater effect to patients with advanced pulmonary arterial hypertension (PAH) by using a combination of two drugs, Treprostinil and Riociquat versus Treprostinil alone

Design

Study type: Interventional Phases: Phase3 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Treprostinil Injectable Product — Injection
  • Drug: Riociguat Pill — Tablet

Primary Outcomes

  • Change in stroke volume/end systolic volume (SV/ESV) (Baseline to 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2019-03-25
Completion: 2025-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Arizona
Principal Investigators:
  • Franz Rischard, DO (PRINCIPAL_INVESTIGATOR) - University of Arizona
Contact Information
Study Contact:
Valerie Boss, MS
520-626-8305
vbloss@email.arizona.edu
Valerie Bloss, MS
520-626-8305
vbloss@email.arizona.edu
University of Arizona
Franz Rischard, DO
University of Arizona
Interventions
  • Drug: Treprostinil Injectable Product — Injection
  • Drug: Riociguat Pill — Tablet
Study Locations (1 sites)
University of Arizona, Tucson, Arizona 85724 United States
Eligibility Criteria
Inclusion Criteria: * WHO Category I PAH * Resting mPAP ≥ 25 mmHg with a wedge pressure of ≤ 15mmHg during right heart catheterization. * Need for parenteral TRE as determined by the PH specialist caring for the patient Exclusion Criteria: * Patients with a mean arterial pressure \<60, and/or requiring vasopressor support * Patients whom expected device (i.e. ECMO, RVAD) assistance or early pulmonary transplantation (within 3 months) seems inevitable * Patients with a left ventricular ejection fraction \<50% or clinical, echocardiographic, and/or catheterization data consistent with heart failure with preserved ejection fraction (HFpEF) and/or moderate-severe aortic or mitral valve abnormality * Patients with severe restrictive lung disease (FVC\<70% predicted) and/or obstructive lung disease (FEV1 \<70% predicted and FEV1/FVC \<70%). * Patients with a history of pulmonary embolism within the last three months or evidence of chronic pulmonary embolism. * Patients with a known contraindication to right heart catheterization. * Patients whom have received active or previous pulmonary vasoactive medication within the previous 12 weeks. * PAH associated with significant venous or capillary involvement (PCWP \> 15 mmHg), known pulmonary veno-occlusive disease, and pulmonary capillary hemangiomatosis. * Pulmonary Hypertension belonging to groups 2 to 5 of the WHO classification. * Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C. * Estimated creatinine clearance \< 30 mL/min * Serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 1.5 times the upper limit of normal. * Hemoglobin \< 75% of the lower limit of the normal range. * Acute or chronic physical impairment (other than dyspnea), limiting the ability to comply with study requirements. * Pregnant or breast-feeding. * Females must either abstain from intercourse (when it is in line with their preferred and usual lifestyle), or * Use 2 medically acceptable, highly effective forms of contraception for the duration of study, and at least 30 after discontinuing study drug. * Known concomitant life-threatening disease with a life expectancy \< 12 months. * Body weight \< 40 kg and/or \>150 kg. * Any condition that prevents compliance with the protocol or adherence to therapy. * Concurrent therapy with strong CYP3A4 inhibitors/inducers (i.e. protease inhibitors, azole antibiotics, macrolides), theophylline, and any medication in the PI's opinion may substantially potentiate the hypotensive effect of RIO. * Treatment with nitrates of any kind within the 4 weeks prior to enrollment. * Known hypersensitivity to drugs of the same class as TRE and/or RIO, or any of their excipients. * Planned treatment, or treatment, with another investigational drug within 1 month prior to randomization. * Recent (\<6 months) hemoptysis and/or history of severe hemoptysis requiring intervention (bronchial artery embolization).
Conditions Hypertension
Phase NA
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

This study seeks to evaluate the impact of a remote patient monitoring (RPM)-specific tech-enabled community health worker workforce on the use of RPM for the management of hypertension among Latinx patients. This study is a step-wedge randomized controlled trial that aims to assess the effectiveness and implementation of RPM-enabled community health workers (CHWs) compared to standard of care RPM hypertension management on blood pressure reduction and evaluate the implementation of the RPM-enabled CHWs for hypertension (HTN) management. The study aims to examine adoption, acceptability, fidelity, cost, sustainability, and equity as outcomes of implementation effectiveness.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Remote Patient Monitoring (RPM)-enabled Community Health Worker (CHW) Support — CHWs will implement RPM by being provided with training modules and implementing electronic health record (EHR) support tools for HTN management.

Primary Outcomes

  • Change in systolic blood pressure (Baseline, Month 18)
  • Change in diastolic blood pressure (Baseline, Month 18)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-10
Completion: 2027-05-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: NYU Langone Health
Collaborators: National Institute on Minority Health and Health Disparities (NIMHD)
Principal Investigators:
  • Devin Mann, MD (PRINCIPAL_INVESTIGATOR) - NYU Langone Health
Contact Information
Study Contact:
Devin Mann, MD
212-263-8313
Devin.Mann@nyulangone.org
Tiffany Martinez
646-501-2505
Tiffany.Martinez@nyulangone.org
Interventions
  • Behavioral: Remote Patient Monitoring (RPM)-enabled Community Health Worker (CHW) Support — CHWs will implement RPM by being provided with training modules and implementing electronic health record (EHR) support tools for HTN management.
Study Locations (1 sites)
NYU Langone Health, New York, New York 10016 United States
Eligibility Criteria
Inclusion Criteria: 1. Self-identify as Latinx 2. Be fluent in English or Spanish 3. Be age 18 years or older 4. Receiving care at one of the 10 safety-net primary care clinics 5. Have uncontrolled HTN documented in the electronic health record (EHR) on at least two visits in the past year (defined as an average BP ≥ 140/90 mmHg) 6. Have been prescribed at least one anti-hypertensive medication and be non-adherent to their medications, defined as adherence \<80% in the preceding 12 months, as determined by prescription orders obtained from the clinic EHR. Exclusion Criteria: 1. Being deemed unable to comply with the study protocol (either self-selected or by indicating during screening that s/he could not complete all requested tasks) 2. Participation in other hypertension-related clinical trials 3. Have significant psychiatric comorbidity or reports of substance abuse (as documented in the EHR) 4. Plan to discontinue care at the clinic within the next 15 months
Conditions Congenital Peumonia, Persistent Pulmonar...
Phase NA
Enrollment 52
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

The aim of the study 1. To evaluate safety and efficacy of melatonin as an adjuvant therapy to inhaled nitric oxide generated by NO generator in the treatment of pulmonary hypertension in full term neonates. 2. To assess the effect of inhaled nitric oxide and melatonin on cerebral perfusion.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Melatonin — Melatonin will be given by nasogastric tube at a dose (3 mg/kg) divided every 8 hours till the end of iNO therapy
  • Device: nitric oxide generator — iNO will be initiated at 20 ppm. The expected clinical response will be improved oxygenation and cardio-respiratory stability in the first 30 minutes after initiation of iNO therapy.If there is no clinical response, the iNO dose will be increased to up to 40 ppm. If after 30 minutes there is no clinical response, iNO will be discontinued

Primary Outcomes

  • melatonin as an adjuvant therapy to iNO (72 hours)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-01
Completion: 2026-12-01
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 52 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ain Shams University
Contact Information
Study Contact:
Sohair Abdelbaset Ali Zayed Dr Sohair, M.BB.CH
01117538132
sohair.abdelbaset@med.asu.edu.eg
Ain Shams University
Interventions
  • Drug: Melatonin — Melatonin will be given by nasogastric tube at a dose (3 mg/kg) divided every 8 hours till the end of iNO therapy
  • Device: nitric oxide generator — iNO will be initiated at 20 ppm. The expected clinical response will be improved oxygenation and cardio-respiratory stability in the first 30 minutes after initiation of iNO therapy.If there is no clinical response, the iNO dose will be increased to up to 40 ppm. If after 30 minutes there is no clinical response, iNO will be discontinued
Study Locations (1 sites)
Ain Shams University, Cairo, Abbassia 00202 Egypt
Eligibility Criteria
Inclusion criteria : * Term neonates with gestational age ≥ 37 weeks. * Mean Pulmonary artery pressure greater than 25mmHg with clinical manifestations as tachypnea, tachycardia, hypoxemia and hypotension Exclusion criteria : * Congenital methemoglobinemia. * Major congenital cardiac anomalies especially duct dependent systemic circulation. * Bleeding tendency. * Patients on other pulmonary vasodilators
Conditions Persistent Pulmonary Hypertension of New...
Phase Not Applicable
Enrollment 60
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

This observational study will seek to describe the uses and safety and efficacy outcomes of treprostinil in clinical practice in patients with persistent pulmonary hypertension (PPHN).

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Primary Outcomes

  • Characteristics of neonates receiving treprostinil in the clinical practice. (From baseline to Day 30 after last dose of treprostinil)
  • Treprostinil-specific treatment patterns. (From baseline to Day 30 after last dose of treprostinil)
  • Number of participants with treatment-related adverse events to evaluate safety. (From baseline to Day 30 after last dose of treprostinil)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-02-25
Completion: 2027-12-31
Eligibility
Age: Up to 44 Weeks
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ferrer Internacional S.A.
Contact Information
Study Contact:
Ferrer MedInfo
609850565
medinfo@ferrer.com
Marine Butin, Medical Doctor
+33 (0)4 27 85 52 84
marine.butin@chu-lyon.fr
CHU Lyon (HCL) - Hopital Femme Mère Enfant
Marine Butin, Medical Doctor
CHU Lyon (HCL) - Hopital Femme Mère Enfant
Interventions
N/A
Study Locations (4 sites)
CHU Lyon (HCL) - Hopital Femme Mère Enfant, Bron, 69500 France
Réanimation néonatale CHU Grenoble Alpes - Hôpital Couple Enfant, Grenoble, 38043 France
CHU Lille - Clinique de Néonatalogie, Lille, 59000 France
CHU de Toulouse Hopital des enfants - Réanimation Néonatale, Toulouse, 31300 France
Eligibility Criteria
Inclusion Criteria: 1. Newborn infants who received at least one dose of IV or SC treprostinil as per clinical practice within 5 years from the moment of data collection. 2. Aged up to 44 weeks after conception at treprostinil initiation. 3. Pulmonary hypertension (PH) or suspicion of PH at the moment of treprostinil initiation. 4. Parent(s) or legally authorized representative(s) provides non-opposition consent for the patient participation in the study. 5. Newborn infants affiliated to French social security. Exclusion Criteria: * None.
Conditions Preeclampsia, Microbiome
Phase Not Applicable
Enrollment 10000
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

major objective This multicenter, prospective cohort study aims at evaluating the predictive value of microbiome ,proteomics and serum markers in preeclampsia. secondary objective to evaluate the value of microbiome,proteomics and serum markers in assessing pregnancy outcome (complications during pregnancy and delivery, delivery) and neonatal prognosis.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Observational studies, The diagnosis was preeclampsia — Observational studies, The diagnosis was preeclampsia

Primary Outcomes

  • microbiome (34 months)
  • proteomics (34 months)
  • metabonomics (34 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-10-19
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 10000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Zhujiang Hospital
Collaborators: Nanfang Hospital, Southern Medical University, Tianjin Central Hospital of Gynecology Obstetrics, Foshan Women's and Children's Hospital, Northwest Women's and Children's Hospital, Xi'an, Shaanxi, First Affiliated Hospital of Wenzhou Medical University
Principal Investigators:
  • hongwei zhou (STUDY_CHAIR) - Zhujiang Hospital
Contact Information
Study Contact:
Sihua Qin
15622136950
274896180@qq.com
Hongwei Zhou, Professor
18688489622
hzhou@smu.edu.cn
Zhujiang Hospital of Southern Medical University
Zhou Hongwei, Professor
18688489622
hzhou@smu.edu.cn
Zhujiang hospital
Interventions
  • Other: Observational studies, The diagnosis was preeclampsia — Observational studies, The diagnosis was preeclampsia
Study Locations (2 sites)
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong 510000 China
Zhujiang hospital, Guangzhou, Guangdong 510000 China
Eligibility Criteria
Inclusion Criteria: * Aged \>=18 years; * Pregnancy woman; * With a singleton pregnancy; * Volunteer and receive regular antenatal examinations in the research centers; * Volunteer to sign a written informed consent. Exclusion Criteria: * Concurrent with hypertension, diabetes, liver and kidney diseases, hematonosis and other serious diseases of pre-pregnancy women, including patients requiring long-term medication for primary diseases; * With history of preeclampsia; * Tumor patients concurrent with serious infection requiring long-term drug treatment; * Pregnant women conceiving through in vitro fertilization; * Multiple pregnancies; * Patients with clear indications of medical pregnancy termination during early pregnancy; * Any medical or non-medical conditions deemed inappropriate for study participation according to the investigator.
Conditions High Blood Pressure (& [Essential Hypert...
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

Cardiovascular rehabilitation is a well-established standard of care that significantly reduces morbidity and mortality while improving quality of life. However, integrating behavioral interventions into physical training may offer additional benefits for autonomic regulation and emotional well-being. This randomized clinical trial aims to investigate the efficacy of adding a brief, guided mindfulness meditation session to a standard cardiovascular rehabilitation program. The study seeks to determine whether this combined intervention enhances blood pressure control, improves perceived quality of life, and increases patient adherence compared to standard rehabilitation alone. Participants newly enrolled in the Cardiac Rehabilitation Service will be randomized into two groups. Both groups will undergo a standard 12-week regimen of aerobic and resistance training combined with optimized medical therapy. The intervention group will additionally receive 15 minutes of voice-guided mindfulness meditation at the end of each exercise session. Key outcome measures include blood pressure variability, quality of life scores (assessed via EQ-5D), and attendance rates.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Meditation — Participants in this group will undergo the standard cardiac rehabilitation program consisting of 60 minutes of aerobic and resistance training, twice a week for 12 weeks. Additionally, they will participate in a 15-minute voice-guided mindfulness meditation session immediately following each exercise session. Participants also receive optimized medical therapy.
  • Procedure: Standard Cardiac Rehabilitation — Participants in this group will undergo the standard cardiac rehabilitation program consisting of 60 minutes of aerobic and resistance training, twice a week for 12 weeks, along with optimized medical therapy. This group does not receive the guided meditation intervention.

Primary Outcomes

  • Quality of Life Scores (EuroQol EQ-5D Visual Analogue Scale) (Baseline and Week 12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-03
Completion: 2028-01-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Instituto Dante Pazzanese de Cardiologia
Contact Information
Study Contact:
GUACIRA GRECCA, MD
55 11 995444126
guagrecca@gmail.com
Instituto Dante Pazzanese de Cardiologia
Interventions
  • Behavioral: Meditation — Participants in this group will undergo the standard cardiac rehabilitation program consisting of 60 minutes of aerobic and resistance training, twice a week for 12 weeks. Additionally, they will participate in a 15-minute voice-guided mindfulness meditation session immediately following each exercise session. Participants also receive optimized medical therapy.
  • Procedure: Standard Cardiac Rehabilitation — Participants in this group will undergo the standard cardiac rehabilitation program consisting of 60 minutes of aerobic and resistance training, twice a week for 12 weeks, along with optimized medical therapy. This group does not receive the guided meditation intervention.
Study Locations (1 sites)
Instituto Dante Pazzanese de Cardiologia, São Paulo, São Paulo 04012909 Brazil
Eligibility Criteria
Inclusion Criteria: * Patients of both sexes, aged 18 years or older. * Newly enrolled in the Phase II Cardiac Rehabilitation Program. * Clinically stable condition with medical clearance to perform aerobic and resistance exercises. * Diagnosis of cardiovascular disease (e.g., coronary artery disease, post-myocardial infarction, post-cardiac surgery, or stable heart failure) warranting rehabilitation. * Willingness and cognitive ability to provide written informed consent. * Availability to attend the twice-weekly sessions for the 12-week duration of the study. Exclusion Criteria: * Current regular practice of meditation, yoga, or other mind-body techniques (defined as formal practice more than once a week in the previous 3 months). * Current participation in other psychological or behavioral intervention clinical trials. * Severe cognitive impairment or psychiatric disorders that preclude understanding of the meditation instructions or group participation (e.g., dementia, untreated psychosis). * Unstable clinical conditions such as unstable angina, uncontrolled arrhythmias, or decompensated heart failure that contraindicate physical exercise. * Significant orthopedic or neurological limitations that prevent the performance of the exercise protocol. * Refusal to participate in the randomization process.